PTGX insider buying and SEC filings, explained
Protagonist Therapeutics, Inc · CIK 1377121
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$15.6M
Planned sales (10b5-1)
$51.9M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 30, 2026 | Planned (10b5-1) | Asif Ali (CFO) sold 58,629 shares at about $141.78 ($8.3M), marked as a 10b5-1 plan trade. Holdings down 50% to 59,003 shares. | SEC filing Filed Oct 2, 2026, 4:10 PM ET |
| Sep 8–10, 2026 | Planned (10b5-1) | Dinesh V. Ph D. Patel (CEO and Director) sold 125,000 shares between Sep 8 and Sep 10 at about $145.92 ($18.2M), marked as a 10b5-1 plan trade. Holdings down 19% to 522,968 shares. | SEC filing Filed Sep 10, 2026 |
| Aug 10–11, 2026 | Planned (10b5-1) | Dinesh V. Ph D. Patel (CEO and Director) sold 100,000 shares between Aug 10 and Aug 11 at about $148.91 ($14.9M), marked as a 10b5-1 plan trade. Holdings down 16% to 523,478 shares. | SEC filing Filed Aug 12, 2026 |
| Jun 23, 2026 | Planned (10b5-1) | William D. Waddill (Director) sold 9,000 shares at about $117.94 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 53% to 7,825 shares. | SEC filing Filed Jun 25, 2026 |
| Jun 10, 2026 | Planned (10b5-1) | William D. Waddill (Director) sold 9,000 shares at about $107.68 ($969K), marked as a 10b5-1 plan trade. Holdings down 53% to 7,825 shares. | SEC filing Filed Jun 11, 2026 |
| May 29, 2026 | Planned (10b5-1) | William D. Waddill (Director) sold 9,000 shares at $99.64 ($897K), marked as a 10b5-1 plan trade. Holdings down 53% to 7,825 shares. | SEC filing Filed Jun 1, 2026 |
| May 12, 2026 | Planned (10b5-1) Amended filing | Dinesh V. Ph D. Patel (CEO and Director) sold 75,000 shares at about $100.12 ($7.5M), marked as a 10b5-1 plan trade. Holdings down 13% to 523,478 shares. This amends a filing from May 12. | SEC filing Filed May 14, 2026 |
| May 7–8, 2026 | Sale | Bryan Giraudo (Director) sold 59,130 shares directly and indirectly (by trust) between May 7 and May 8 at about $100.10 ($5.9M). Direct holdings down 76% to 12,695 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 11, 2026 |
| Apr 20, 2026 | Sale | Asif Ali (CFO) sold 1,750 shares at $105.47 ($185K). Holdings down 3% to 59,003 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 21, 2026 |
| Jan 27, 2026 | Sale | Asif Ali (CFO) sold 46,203 shares at about $83.13 ($3.8M). Holdings down 43% to 60,320 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 27, 2026 |
| Jan 23, 2026 | Sale | Arturo Md Molina (Chief Medical Officer) sold 13,151 shares at about $82.42 ($1.1M). Holdings down 14% to 84,115 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 27, 2026 |
| Jan 20, 2026 | Sale | Arturo Md Molina (Chief Medical Officer) sold 9,514 shares at $82.48 ($785K). Holdings down 9% to 97,266 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 21, 2026 |
| Jan 20, 2026 | Sale | Dinesh V. Ph D. Patel (CEO and Director) sold 34,438 shares at $82.48 ($2.8M). Holdings down 6% to 580,505 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 21, 2026 |
| Jan 20, 2026 | Sale | Asif Ali (CFO) sold 8,588 shares at $82.48 ($708K). Holdings down 10% to 78,077 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 21, 2026 |
| Nov 17, 2025 | Sale | Arturo Md Molina (Chief Medical Officer) sold 2,712 shares at $84.77 ($230K). Holdings down 3% to 81,180 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 19, 2025 |
37 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow PTGX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.